LOS ANGELES, Aug. 2, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ: MRNA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Moderna issued a press release on May 31, 2024, disclosing that "the U.S. Food and D ...

COVID-19 vaccine maker Moderna, Inc. MRNA fell over 21% on Thursday after the company reduced its revenue guidance for the year, citing a highly competitive respiratory vaccine market in the U.S. and weak COVID-19 vaccine sales in Europe. What Happened: Moderna stock plunged 21.01% to $94.17 on Thursday and fell an incremental 1.73% to $92.54 in premarket trading on Friday, according to Benzinga Pro data. Cathie Wood's Ark Invest capitalized on the weakness and piled into the stock. On Thursday two of Ark's ...

hapabapa Moderna: Endured A 20% Fall Yesterday Moderna, Inc. (NASDAQ:MRNA) investors endured a torrid earnings release that added more pressure on MRNA, as the stock has declined almost 45% from its May 2024 highs. As a result, there's no doubt that it has plunged firmly into a bear market as the market reassessed its optimism about the embattled MRNA Covid vaccine maker. While the world wants to move on from Covid, it should be noted that the dreaded disease isn't expected to disappear. The World Health Or ...

Key Takeaways The S&P 500 fell 1.4% on Thursday, Aug. 1, ahead of the latest tech earnings reports and as several data points raised concerns about the health of the U.S. economy. Moderna shares tumbled after the biopharma firm cut its full-year revenue forecast, citing reduced demand for its COVID-19 vaccine in Europe. Implementation of a cost-efficient operating model helped freight transporter C.H. Robinson beat earnings estimates, and its shares moved higher. Major U.S. equities indexes moved lower on t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _ Commission File Number: 001-38753 Moderna, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 81-3467528 (State or Other Jurisdiction of ...

U.S. stocks traded lower toward the end of trading, with the Dow Jones index dipping more than 650 points on Thursday. The Dow traded down 1.61% to 40,184.39 while the NASDAQ fell 2.77% to 17,111.79. The S&P 500 also fell, dropping, 1.78% to 5,424.16. Leading and Lagging Sectors Utilities shares gained by 1.5% on Thursday. In trading on Thursday, information technology shares fell by 4%. Top Headline Moderna Inc MRNA stock dipped more than 20% on Thursday as the company lowered its 2024 sales guidance due t ...

Moderna, Inc. MRNA shares are getting hit because of a bad earnings report. The Street didn't like the numbers. The shares have broken a support level and may form a new downtrend. This is why Moderna is our Stock of the Day. If a stock is trending lower, there is more supply than demand. There aren't enough buy orders to absorb all of the sell orders. The market is out of equilibrium. If the stock reaches support, the dynamics change. There is enough demand to absorb the supply. For every sell order, there ...

Moderna Inc. (NASDAQ:MRNA) Q2 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants St??phane Bancel - Chief Executive Officer Stephen Hoge - President Jamey Mock - Chief Financial Officer Lavina Talukdar - Senior Vice President, Investor Relations Conference Call Participants Salveen Richter - Goldman Sachs Terence Flynn - Morgan Stanley Michael Yee - Jefferies Elliott Bosco - UBS Gena Wang - Barclays Luca Issi - RBC Capital Alexandria Hammond - Bank of America Edward Tenthoff - Pi ...

Second Quarter 2024 Financial Results August 1, 2024 mode © 2024 Moderna, Inc. All rights reserved. Forward-looking statements and disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's expected product sales in 2024 and trends informing Moderna's 2024 sales outlook; Moderna's ability to meet the 2024/2025 respiratory virus season demand and to drive vaccination rates; ...

Moderna, Inc. (MRNA) reported a loss of $3.33 per share in second-quarter 2024, narrower than the Zacks Consensus Estimate of a loss of $3.47. In the year-ago period, management posted a loss of $3.62. Revenues in the quarter were $241 million, beating the Zacks Consensus Estimate of $124.9 million. Total revenues declined 30% year over year due to reduced COVID-19 vaccine sales during the quarter. Quarter in Detail Product sales, entirely from the sale of COVID-19 vaccines, were down 37% year over year to ...